Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
ACAPODENE®and, ACAPODENE®in, ACAPODENE®or, ACAPODENE®within, Adult, Advair, AFUD, agonist, ANDA, bachelor, back, baseline, Baylor, beta, Brady, capacity, cardioprotective, chemoprevention, Chilcott, Christopher, colorectal, Columbia, consecutive, Conzen, culmination, deadline, Deficiency, deliverable, Dentistry, Dermatology, description, dollar, dual, Duke, durable, embolism, entirety, ESS, extremity, FARESTON®to, fellowship, femur, Fixed, foregoing, Fuqua, GAAP, guaranteed, Hesselberg, Houston, immobilization, Immunex, induced, inflammation, installment, Investmentsin, Jeff, Jeffrey, Jersey, Jr, Lambert, Landlord, lessor, leukemia, Likewise, lung, lymphocytic, lymphoma, mentioned, mild, Military, monthly, Morton, NAV, nonfinancial, nonrefundable, ocular, orderly, OstarineTMand, OstarineTMdrug, OstarineTMfor, plc, pooled, postdoctoral, prespecified, proper, Puget, purport, radiograph, reclassification, recurring, reevaluated, Ronald, Scholar, Sound, South, steering, subset, substance, substantive, suitable, SUSA, tadalafil, tenant, thereunder, tiered, tone, tool, Translational, unclear, undelivered, unrealized, upward, Valtrex, VTE, Warner, Wood
Removed:
Abbott, achieving, Advisor, amend, Amherst, amortize, andromustine, area, Asian, ATAC, Biochemistry, Biomed, Bird, Boger, CellCeptTransplant, ChemSyn, Children, component, construction, continuously, creating, culture, Deputy, direction, discounted, EaglePicher, eventually, expert, extending, fellow, forma, GCP, gene, Harvard, identifying, Immunology, Invertebrate, involvement, IPO, Jude, Karen, kill, kind, Leader, Mayo, median, midpoint, Mississippi, negotiating, nephrology, obstruction, poor, pro, prostarine, Quotation, refractory, reimbursed, remission, Renin, Roche, Science, Scientist, shortened, shrink, St, stage, studying, superseded, tract, Transplantation, undiscounted, unsuccessful, unvested, urinary, Venture, Veverka, viral, Zoology
Filing tables
Filing exhibits
- 10-K Annual report
- 10.43 EX-10.43 Exclusive License and Collaboration Agreement
- 10.44 EX-10.44 2008 Compensation Information for Registrant's Executive Officers
- 10.45 EX-10.45 Non-employee Director Compensation Arrangements
- 10.46 EX-10.46 Sublease Agreement
- 12.1 EX-12.1 Statement of Compensation of Deficiency of Earnings Available to Cover Fixed Charges
- 23.1 EX-23.1 Consent of Independent Registered Public Accounting Firm
- 31.1 EX-31.1 Section 302 Certification of the CEO
- 31.2 EX-31.2 Section 302 Certification of the CFO
- 32.1 EX-32.1 Section 906 Certification of the CEO
- 32.2 EX-32.2 Section 906 Certification of the CFO
Related press release
ONCT similar filings
Filing view
External links
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U. S. C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
18 U. S. C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of GTx, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2007, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Mitchell S. Steiner, Chief Executive Officer of the Company certify, pursuant to Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: March 11, 2008
/s/ Mitchell S. Steiner
Mitchell S. Steiner, M.D., F.A.C.S.
Chief Executive Officer and
Vice-Chairman of the Board of Directors
Mitchell S. Steiner, M.D., F.A.C.S.
Chief Executive Officer and
Vice-Chairman of the Board of Directors
This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934 (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.